Table 1. Patient demographics and clinical data of patients with upper gastrointestinal bleeding.

	Non-rebleeding patients (n = 316, 85.18%)	Rebleeding patients (n = 55, 14.72%)	p value
Age (years)	61 (47–75)	63 (49–73)	0.807
Gender (male)	215 (68%)	38 (69.1%)	0.87
Co-morbidities
Diabetes mellitus	54 (17.1%)	7 (12.72%)	0.424
Congestive heart failure	15 (4.75%)	6 (10.9%)	0.076
Liver disease	20 (6.33%)	4 (7.27%)	0.793
Hypertension	100 (31.6%)	21 (38.2%)	0.341
History of stroke	20 (6.3%)	4 (7.3%)	0.793
Chronic kidney disease	38 (12%)	7 (12.7%)	0.883
Cancer	21 (6.6%)	14 (25.5%)	<0.001
Medication
NSAIDs	47 (14.9%)	4 (7.3%)	0.14
Antiplatelet	40 (12.7%)	5 (9.1%)	0.457
Anticoagulants	28 (8.9%)	3 (5.5%)	0.404
Chief complaint
Dizziness	11 (3.5%)	0 (0%)	0.32
Palpitation	4 (1.27%)	0 (0%)	0.754
Fatigue	19 (6%)	5 (9.1%)	0.39
Bloody or coffee-ground vomitus	144 (45.6%)	37 (67.3%)	0.004
Rectal bleeding	4 (1.27%)	1 (1.81%)	0.744
Abdominal pain	11 (3.48%)	0 (0%)	0.325
Syncope	12 (3.80%)	0 (0%)	0.295
Dark tarry stool	111 (35.12%)	12 (21.82%)	0.056
Instable hemodynamics at presentation	55 (17.4%)	14 (25.5%)	0.157
Hematochezia	9 (2.8%)	3 (5.5%)	0.322
Melena	212 (67.1%)	37 (67.3%)	0.979
Blood in gastric tube	88 (27.8%)	24 (43.6%)	0.019
In-hospital mortality	1 (0.3%)	7 (12.7%)	<0.001
30-day mortality	5 (1.6%)	8 (14.5%)	<0.001

Note:

NSAIDs, non-steroidal anti-inflammatory drugs. Bold font indicates statistical significance.